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ABSTRACT

A novel computational method and generation of mutant

butyrylcholinesterase for cocaine hydrolysis is provided. The
method includes molecular modeling a possible BChE
mutant and conducting molecular dynamics simulations and
hybrid quantum mechanical/molecular mechanical calcula
tions thereby providing a screening method of possible BChE
mutants by predicting which mutant will lead to a more stable
transition state for a rate determining step. Site-directed

mutagenesis, protein expression, and protein activity is con
ducted for mutants determined computationally as being
good candidates for possible BChE mutants, i.e., ones pre

dicted to have higher catalytic e?iciency as compared with
wild-type BChE. In addition, mutants A199S/A328W/

Y332G, A199S/F227A/A328W/Y332G, A199S/S287G/

A328W/Y332G,
and

A199S/F227A/S287G/A328W/Y332G,

A199S/F227A/S287G/A328W/E441D

Yang, Wenchao et al., Characterization of a high-activity mutant of

human butyrylcholinesterase against (—)-cocaine, Chemico-Biologi
cal Interactions, 2010, vol. 187, pp. 148-152.

all

have

enhanced catalytic ef?ciency for (—)-cocaine compared with
wild-type BChE.
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HIGH-ACTIVITY MUTANTS OF
BUTYRYLCHOLINESTERASE FOR
COCAINE HYDROLYSIS AND METHOD OF
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RELATED APPLICATIONS
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This application is a division of and claims bene?t to US.

patent application Ser. No. 13/449,107, now allowed, which
is a division of and claims bene?t to US. patent application
Ser. No. 13/018,641, now issued as US. Pat. No. 8,193,327,
?led Feb. 1, 201 1, which is a division ofand claims bene?t to
US. patent application Ser. No. 12/752,920, now issued as
US. Pat. No. 7,919,082, ?ledApr. 1, 2010, which is a division
of and claims bene?t to US. patent application Ser. No.
12/192,394, now issued as US. Pat. No. 7,731,957, ?ledAug.
15, 2008, which is a division of and claims bene?t to US.
patent application Ser. No. 11/243,111, now issued as US.
Pat. No. 7,438,904, ?led Oct. 4, 2005. The contents of which

are incorporated herein by reference in their entirety.
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GOVERNMENT INTEREST

Subject matter described herein was made with govem
ment support under Grant Number R01DA013930 awarded

by the National Institute on Drug Abuse (NIDA) of the
National Institutes of Health (NIH). The government has
certain rights in the described subject matter.

(+)—cocaine
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OH
+

FIELD OF THE INVENTION
30

O=C

O

The present invention relates to butyrylcholinesterase vari

ant polypeptides, and in particular, butyrylcholinesterase
mutants having amino acid substitutions.
BACKGROUND OF THE INVENTION

OCH;

Cocaine abuse is a major medical and public health prob
lem that continues to defy treatment. The disastrous medical
and social consequences of cocaine addiction, such as violent

crime, loss in individual productivity, illness and death, have
made the development of an effective pharmacological treat
ment a high priority. However, cocaine mediates its reinforc

40

ester, whereas the oxidation produces norcocaine. The
metabolite ecgonine methyl ester is a biologically inactive
metabolite, whereas the metabolite norcocaine is hepatotoxic

and the classical pharmacodynamic approach has failed to
yield small-molecule receptor antagonists due to the di?icul
45

based approaches is to interfere with the delivery of cocaine
to its receptors and accelerate its metabolism in the body.
The dominant pathway for cocaine metabolism in primates

is butyrylcholinesterase (BChE)-catalyzed hydrolysis at the
benzoyl ester group (Scheme 1).
H3C

Scheme 1. Schematic representation of BChE-catalyzed
hydrolysis at the benzoyl ester group.
Only 5% of the cocaine is deactivated through oxidation by
the liver microsomal cytochrome P450 system. Cocaine

hydrolysis at benzoyl ester group yields ecgonine methyl

ing and toxic effects by blocking neurotransmitter reuptake
ties inherent in blocking a blocker. An alternative to receptor

OH

35

and a local anesthetic. BChE is synthesized in the liver and

widely distributed in the body, including plasma, brain, and
lung. Extensive experimental studies in animals and humans
demonstrate that enhancement of BChE activity by adminis
tration of exogenous enzyme substantially decreases cocaine

50

H

half-life.
Enhancement of cocaine metabolism by administration of
BChE has been recognized to be a promising pharmacoki

netic approach for treatment of cocaine abuse and depen

\ /
N+

dence. However, the catalytic activity of this plasma enzyme
is three orders-of-magnitude lower against the naturally
occurring (—)-cocaine than that against the biologically inac

O

OCH;

t

H20

tive (+)-cocaine enantiomer. (+)-cocaine can be cleared from
plasma in seconds and prior to partitioning into the central
nervous system (CNS), whereas (—)-cocaine has a plasma

BChE
—’

half-life of approximately 45-90 minutes, long enough for
O

60

/

manifestation of the CNS effects which peak in minutes.

Hence, BChE mutants with high activity against (—)-cocaine
are highly desired for use in humans. Although some BChE

(—)—cocaine

65

mutants with increased catalytic activity over wild-type
BChE have previously been generated, there exists a need for
mutant BChE with even higher catalytic activity. Thus, prior
mutants provide limited enhancement in catalytic activity
over wild-type BChE.

US 8,835,150 B1
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Previous studies such as (a) Masson, P.; Legrand, P.; Bar

The main difference between the experimentally deter

tels, C. E; Froment, M-T.; Schopfer, L. M.; Lockridge, 0.
Biochemistry 1997, 36, 2266 (b) Masson, P.; Xie, W., Fro
ment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret, C.; Lock
ridge, O. Biochim. Biophys. Acta 1999, 1433, 281, (c) Xie,
W.; Altamirano, C. V.; Bartels, C. E; Speirs, R. J.; Cashman,
J. R.; Lockridge, 0. Mol. Pharmacol. 1999, 55, 83, (d) Duy

mined BChE structure and its model was found at the acyl

binding pocket (acyl loop) that is signi?cantly bigger than
expected. It is unclear whether the structural difference at the

acyl binding pocket signi?cantly affect BChE binding with
(—)-cocaine and (+)-cocaine. Although previous MD simula
tions of cocaine binding with wild-type BChE and the reac
tion coordinate calculations point to some amino acid resi
dues that might need to be mutated for the purpose of

sen, E. G.; Bartels, C. E; Lockridge, O. J. Pharmacol. Exp.

Ther. 2002, 302, 751, (e) Nachon, E; Nicolet,Y.; Viguie, N.;

improving the catalytic activity for (—)-cocaine hydrolysis, it

Masson, P.; Fontecilla-Camps, J. C.; Lockridge, 0. Eur. J.
Biochem. 2002, 269, 630, (f) Zhan, C.-G.; Landry, D. W. J.
Phys. Chem. A 2001, 105, 1296; Berkman, C. E.; Underiner,
G. E.; Cashman, J. R. Biochem. Pharmcol. 1997, 54, 1261;

(g) Sun, H.; Yazal, J. E.; Lockridge, O.; Schopfer, L. M.;
Brimijoin, S.; Pang,Y.-P. J. Biol. Chem. 2001, 276, 9330, (h)
Sun, H.; Shen, M. L.; Pang,Y. P.; Lockridge, O.; Brimijoin, S.
J. Pharmacol. Exp. Ther. 2002, 302, 710, Sun, H.; Pang,Y.
P.; Lockridge, O.; Brimijoin, S. Mol. Pharmacol. 2002, 62,
220 (hereinafter “Sun et al”); and (j) Zhan, C.-G.; Zheng, E;

remained unknown which exact amino acid mutations will

result in a BChE with a higher catalytic activity for (—)
cocaine.
Computational studies of wild-type BChE and cocaine
from Sun, et al, based on a “homology model,” suggest that

the rate-determining step for BChE-catalyzed hydrolysis of
cocaine is the rotation of the cocaine in the active site of

20

BChE. By decreasing the hindrance of the rotation, the rate of
the hydrolysis may be enhanced. Sun, et al describes creating
an A328W/Y332A BChE mutant by: (1) replacing Tyr332

Landry, D. W. J. Am. Chem. Soc. 2003, 125, 2462 (hereinafter

with Ala, “to reduce the steric hindrance and the 313-313 interac

“Zhan et al”), herein all incorporated by reference, suggested
that, for both (—)-cocaine and (+)-cocaine, the BChE-sub

tion that impede rotation,” and (2) replacingA1a328 with Trp

strate binding involves two different types of complexes:

non-prereactive and prereactive BChE-substrate complexes.

25

Whereas the non-prereactive BChE-cocaine complexes were
?rst reported by Sun et al, Zhan et al were the ?rst reporting
the prereactive BChE-cocaine complexes and reaction coor
dinate calculations, disclosed in Zhan et al.
It was demonstrated that (—)/(+)-cocaine ?rst slides down
the substrate-binding gorge to bind to W82 and stands verti

30

cally in the gorge between D70 and W82 (non-prereactive

computationally generated 3D model of wild-type BChE and
changing the relevant residues using commercially available
software. Cocaine was docked to the catalytic gorge of the
35

complex, cocaine lies horizontally at the bottom of the gorge.
The main structural difference between the BChE-(—)-co

caine complexes and the corresponding BChE-(+)-cocaine

mutant BChE using other commercially available software.
The cocaine-enzyme complex was re?ned by molecular
dynamic simulation. The data generated by the molecular
modeling studies were consistent with enzyme assays and
kinetic data.

complexes exists in the relative position of the cocaine methyl
ester group. Reaction coordinate calculations revealed that

studied using molecular modeling. The three dimensional
(3D) structure of A328W/Y332A was generated from the

complex) and then rotates to a position in the catalytic site
within a favorable distance for nucleophilic attack and

hydrolysis by S198 (prereactive complex). In the prereactive

“to provide a cation-n interaction to restore substrate a?inity
lost in disabling the 313-313 interaction.”
Sun et al studied the A328W/Y332A BChE mutant using
enzyme assays and kinetics. In vitro studies were conducted
using human plasma and in vivo studies were conducted
using male Sprague-Dawley rats. The mutant was found to
have enhanced catalytic properties. The mutant was further

40

It should be noted that all prior computational techniques

the rate-determining step of BChE-catalyzed hydrolysis of

(molecular docking and molecular dynamics simulation)

(+)-cocaine is the chemical reaction process, whereas for

used by other researchers are based on an empirical force ?eld
which cannot be used to perform any necessary reaction
coordinate calculation for the detailed understanding of the

(—)-cocaine the change from the non-prereactive complex to
the prereactive complex is rate determining. A further analy
sis of the structural changes from the non-prereactive com

45

plex to the prereactive complex reveals speci?c amino acid
residues hindering the structural changes, providing initial
clues for the rational design of BChE mutants with improved

catalytic activity for (—)-cocaine.
Previous molecular dynamics (MD) simulations of prere

50

active BChE-cocaine binding were limited to wild-type

BChE. Even for the non-prereactive BChE-cocaine complex,
only one mutant (A328W/Y332A) BChE binding with (—)
cocaine was simulated and its catalytic activity for (—)-co
caine was reported by Sun et al. No MD simulation was

complicated catalytic reaction process. As it is well-known, it
is particularly challenging to model and simulate the detailed
reaction pathway and predict the kinetics of such an enzy
matic reaction.
U.S. Patent Application Publication Nos. 2004/0121970;
2004/0120939; and 2003/0153062, describe 20+BChE
mutants, or “variants,” from human and other animals, each
having from one to six amino acid alterations and increased

55

cocaine hydrolysis activity. For example, mutants include
F227A/A328W; F227A/S287G/A328W; A119S/S287G/
A328W; A328W/Y332M/S287G/F227A, A199S/F227A/S/

performed on any prereactive enzyme-substrate complex for

287G/A328W and A119S/F227A/S287G/A328W/Y332M.

(—)- or (+)-cocaine binding with a mutant BChE. In addition,
all previous computational studies of Sun et al and Zhan et al

The mutants have varying increases in catalytic activity, up to
100-fold increase relative to wild-type BChE.

of BChE interacting with cocaine were performed based on a

homology model of BChE when three-dimensional (3D)

There exists a need in the art for determining which pro

X-ray crystal structure was not available for BChE, as taught

posed mutant BChEs should have ever increasing catalytic
activity and for generating those mutants which should have

by Nicolet,Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps,

enhanced catalytic activity.

60

J. C.; Nachon, F. J. Biol. Chem. 2003, 278, 41141 (hereinafter
“Nicolet et al”), recently reported 3D X-ray crystal structures
of BChE. As expected, the structure of BChE is similar to a

previously published theoretical model of this enzyme and to
the structure of acetylcholinesterase.

SUMMARY OF THE INVENTION
65

The present invention includes ?ve novel human BChE

mutants that have unexpected increased catalytic e?iciency

US 8,835,150 B1
5

6

for cocaine hydrolysis. The mutants have various unique
amino acid residue substitutions which provide the surprising
enhanced catalytic activity. These mutants are (1) A199S/

plex catalytic mechanism of cocaine hydrolysis, makes it
dif?cult to improve the catalytic activity of BChE for cocaine

hydrolysis.

A328W/Y332G mutant (SEQ ID NO: 2), which has a

The present invention in one form, concerns a butyrylcho

approximately 65-fold improved catalytic ef?ciency against
(—)-cocaine; (2) A199S/F227A/A328W/Y332G mutant

linesterase variant peptide comprising an amino acid
sequence selected from the group consisting of SEQ ID NOS:

(SEQ ID NO: 8), which has an approximately 148-fold

2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30.

improved catalytic ef?ciency against (—)-cocaine; (3) A1 99S/

The present invention in another form thereof concerns a

S287G/A328W/Y332G mutant (SEQ ID NO: 14), which has

nucleic acid molecule comprising a nucleic acid sequence
which encodes a butyrylcholinesterase variant peptide, the
nucleic acid sequence selected from the group consisting of

an approximately 456-fold improved catalytic ef?ciency

against (—)-cocaine; (4) A199S/F227A/S287G/A328W/
Y332G mutant (SEQ ID NO: 20), which has an approxi

SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27,

mately 1.003-fold improved catalytic ef?ciency against (—)
cocaine; and (5) A199S/F227A/S287G/A328W/E441D

and 29.
The present invention in another form thereof concerns a

mutant (SEQ ID NO: 26), which has an approximately 445

pharmaceutical composition comprising a butyrylcholinest

fold improved catalytic ef?ciency against (—)-cocaine.

erase variant polypeptide comprising an amino acid sequence

In addition, the aforementioned mutant amino acid
sequences can be truncated without substantially affecting
the catalytic activity so that amino acid residues 1-67 and
443-574 can be removed without substantially affecting the

selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8,
10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30; and a suitable

pharmaceutical carrier.
20

The present invention in another form thereof concerns a

method for treating a cocaine-induced condition comprising

catalytic activity of the enzyme. SEQ ID NOS: 4, 10, 16, 22
and 28 are the amino acid sequences for residue 68-142

administering to an individual an effective amount of butyryl

corresponding to mutants 1-5, respectively. In addition, with

cholinesterase variant peptide having an amino acid sequence

regard to mutants 1-4, it was found that amino acid residues
before 117 and after 438 could be removed without substan

25

tially changing the activity of the mutant enzymes, resulting
in truncated amino acid sequences having SEQ ID NOS: 6,
12, 18 and 24, respectively. Finally with regard to mutant 5,

cocaine concentration.
The present invention is another form thereof concerns a

method for treating a cocaine induced condition comprising

amino acid residues before 117 and after 441 could be

removed without substantially changing its activity resulting

administering to an individual an effective amount of a phar
30

group consisting ofSEQ ID NOS. 2, 4, 6, 8, 10, 12, 14, 16, 18,
20, 22, 24, 26, 28, and 30, and suitable pharmaceutical carrier
of claim 3 to an individual in an effective amount to lower
35

with a suitable pharmaceutical carrier. The pharmaceutical
composition can be administered to an individual in an effec

tive amount to lower the patient’s cocaine blood concentra

tion and in particular (—)-cocaine blood concentration.

maceutical composition comprising a butyrylcholinesterase
variant having an amino acid sequence selected from the

in SEQ ID NO: 30.
These aforementioned truncated sequences all of with
similar catalytic activity is based on protein structures.
Further, the present invention is directed to a novel and

unique pharmaceutical composition which comprises a
butyrylcholinesterase variant, namely mutants 1-5, along

selected from the group consisting of SEQ ID NOS. 2, 4, 6, 8,
10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30, to lower blood

40

blood cocaine concentration.
The present invention in yet another form thereof concerns
a method for generating butyrylcholinesterase mutants. The
method includes generating an initial structure of the transi
tion state structure for the rate-determining step of the

cocaine hydrolysis catalyzed by a possible butyrylcholinest

In addition, the present invention is directed to a novel and

erase mutant. A suf?ciently long time molecular dynamics

unique method for developing mutants which have enhanced
catalytic ef?ciency. The generation method includes both a

simulation is performed on the transition state structure in
water to have a stable molecular dynamics trajectory. The

molecular dynamics trajectory is analyzed and the hydrogen

computational portion and an experimental portion. With
regard to the computational portion, a variety of state of the

45

art computational techniques including molecular modeling,
molecular dynamics (MD) simulations and hybrid quantum
mechanical/molecular mechanical (QM/MM) calculations,
provide a virtual screening of possible BChE mutants. This
virtual screening predicts which mutation will lead to a more
stable transition state for a rate-determining step compared to

50

(—)-cocaine benzyl ester and the wild-type butyrylcholinest
erase, optionally, hybrid quantum mechanical/molecular
mechanical (QM/MM) geometry optimization is performed

the corresponding separated reactants, i.e., free cocaine and
free enzyme. The more stable the transition state, the lower

the energy barrier, and the higher the catalytic ef?ciency.
Following the computational portion, an experimental test is

bonding energies are estimated between the carboxyl oxygen
of the (—)-cocaine benzyl ester and the oxyanion hole of the
possible butyrylcholinesterase mutant. If the overall hydro
gen binding energy between the carboxyl oxygen of the (—)
cocaine benzyl ester and the possible butyrylcholinesterase
mutant, in the transition state, is stronger than the overall
hydrogen binding energy between the carboxyl oxygen of the

portion. The experimental test includes site-directed

to re?ne the molecular dynamics-simulated structure, the
hydrogen binding energies are calculated and the energy bar
rier is evaluated. Finally, the butyrylcholinesterase mutant is

mutagenesis, protein expression, and enzyme activity assay.

generated.

55

then conducted on the possible mutants of the computation

In various alternative embodiments, the generating an ini

The experimental tests are conducted on mutants which are

predicted to have a high catalytic ef?ciency against (—)-co

60

tion coordinate calculations for the wild-type butyrylcho
linesterase. The generating butyrylcholinesterase mutant

caine than the wild-type BChE and/or other known BChE

mutants against (—)-cocaine. Thus, the present method iden
ti?es or predicts mutants having high catalytic activity for

includes performing site-directed mutagenesis on a nucleic

cocaine hydrolysis by performing molecular modeling and
MD simulations on the transition state structures of possible
mutants of BChE. This method is an improvement over tra

ditional random-search approaches, which, given the com

tial structure of the transition state structure is based on reac

acid sequence which includes wild-type butyrylcholinest
65

erase to generate the mutant butyrylcholinesterase nucleic

acid sequence. Using the mutant butyrylcholinesterase
nucleic acid sequence, the protein encoded by the mutant

US 8,835,150 B1
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nucleic acid sequences is expressed to produce mutant

active site from the non-prereactive complex to the prereac
tive complex in accordance with the present invention.
FIG. 4A depicts the (—)-cocaine rotation in the active site of
A328W/Y332A; FIG. 4B depicts the (—)-cocaine rotation in
the active site of A328W/Y332G BChE from the non-preac

butyrylcholinesterase and catalytic activity assay is per
formed on the mutant butyrylcholinesterase.

The hybrid quantum mechanical/molecular mechanical
geometry optimization may include calculating the hydrogen
binding energies and evaluating the energy barriers only if the
overall hydrogen binding energy between the carboxyl oxy
gen of the (—)-cocaine benzyl ester and the possible butyryl

5

tive complex to the prereactive complex; and FIG. 4C depicts
the (—)-cocaine rotation in the active site of wild-type BChE.
FIG. 5A is a plot of the key internuclear distances (in A)
versus the time in the simulated TSl structure for (—)-cocaine

cholinesterase mutant, in the transition state, is stronger than

hydrolysis catalyzed by A328W/Y332A; and FIG. 5B for

known butyrylcholinesterase mutants against (—)-cocaine.

Al 99S/A328W/Y332G BChE.

In yet another alternative further embodiment, the method
for generating butyrylcholinesterase mutants further includes

FIG. 6 is a plot of key internuclear distances (in A) versus
the time in the simulated TSl structure for (—)-cocaine

hydrolysis catalyzed by Al 99S/S287G/A328W/Y332G

determining the rate-limiting step in the hydrolysis of (—)

BChE.

cocaine by the possible butyrylcholinesterase mutant by con
ducting molecular dynamics simulations and quantum

DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENTS

mechanical/molecular mechanical calculations relating to the
transition states for other reaction steps between (—)-cocaine

by the possible butyrylcholinesterase mutant and calculating
respective energy barriers, thereby establishing which of the

20

reaction steps is the rate-determining one.
BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 are plots of distances in the MD simulation (—)
cocaine binding with A328W/Y332G BChE versus the simu

lation time, along with root-mean-square deviation (RMSD)
in the enzyme-substrate complexes where FIG. 1A represents
the non-prereactive enzyme-substrate complexes; and FIG.
1B represents the prereactive enzyme-substrate complexes in

25

The present invention has two major improvements over
the prior art. The ?rst is the presently discovered BChE
mutants, mutant 1, Al99S/A328W/Y332G; mutant 2,
Al99S/F227A/A328W/Y332G; mutant 3, A199S/S287G/
A328W/Y332G; mutant 4, Al99S/F227A/S287G/A328W/
Y332G; and mutant 5, Al99S/F227A/S287G/A328W/

E44lD each have a signi?cantly higher catalytic ef?ciency.
The second improvement is concerning the mutant designing
or discovering process.
The BChE mutants 1-5 have full length amino acid

sequences, SEQ ID NOS: 2, 8, 14, 20, and 26, respectively,
30

which are encoded by nucleic acid sequences having SEQ ID

NOS: 1, 7, l3, l9, and 25, respectively. Table 1 summarizes

accordance with the present invention.
FIG. 2 shows the binding of structures of the simulated

the catalytic ef?ciency against (—)-cocaine for the ?ve

non-prereactive and prereactive complexes of wild-type

mutants.

In addition to the full length BChE mutants, the respective

BChE binding with two entomers of cocaine in which FIG.

2A depicts BChE (—)-cocaine non-prereactive complex; FIG.
2B depicts BChE (—)-cocaine prereactive complex, FIG. 2C
depictes BChE (+)-cocaine non-prereactive complex; and
FIG. 2D depicts BChE (+)-cocaine prereactive complex.
FIG. 3A shows the (—)-cocaine rotation in the BChE active
site for the non-prereactive complex to the prereactive com

plex hindered by some residues at positions Y332, A328, and
F329 residues in the non-prereactive complexes which are
signi?cantly different from the corresponding positions in the
prereactive complex; and FIG. 3B shows the (+)-cocaine

35

amino acid sequence can be truncated without substantially

affecting the respective catalytic activity. With all mutants,
residues 1-67 and 443-574 can be removed without substan

tially affecting the catalytic activity of the respective mutant
40

BChE. Further, with regard to mutant 1-4, amino acids 1-1 16
and 439-574 canbe omitted without substantially affecting its

respective catalytic activity. With regard to mutant 5, amino
acid residues 1-116 and 442-574 can be omitted without

substantially affecting its catalytic activity. Table 1 also pro

rotation in the BChE active site where none of the aforemen

vides a summary of amino acid SEQ ID NOS and correspond
ing nucleic acid SEQ ID NOS for the aforementioned trun

tioned residues hinders the (+)-cocaine rotation in the BChE

cated mutant BChE sequences.

TABLE 1

Partially

Mutant

Amino
Acid
Substi—

Number

tuting

1

A199S/
A328W/

2

Y332G
A199S/F

Truncated Nucleic
SEQ ID
SEQ ID NO
Nucleic Amino
Acid Sequence
NO. for
Corresponding SEQ ID NO.
Acid
Acid Corresponding To Amino Acid To Amino Acid
for Amino
SEQ ID SEQ ID
Amino Acid
Residues
Residues
Acid Residues
NO.

Catalytic
Ef?ciency
Against

NO.

Residues 68—442

68—442

117-43 8/441 *

117-43 8/441 *

(—)—cocaine

1

2

3

4

5

6

65-fold

7

8

9

10

11

12

148-fold

13

14

15

16

17

18

456-fold

227NA
328W/Y
3

332G
A1995/S

287G/A
328W/Y
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TABLE 1-continued

Partially
SEQ ID NO
Corresponding SEQ ID NO.
To Amino Acid
for Amino
Residues
Acid Residues

Number

tuting

NO.

NO.

Residues 68—442

68—442

117—43 8/441*

117-43 8/441 *

Catalytic
Ef?ciency
Against
(—)—cocaine

4

A1995/F
227NS2
87G/A3
28W/Y 3
32G
A1995/F
227NS2
87G/A3
28W/E4
41D

19

20

21

22

22

24

1,003-fold

25

26

27

28

29

30

445-fold

Mutant

5

Amino
Acid
Substi—

Truncated Nucleic
SEQ ID
Nucleic Amino
Acid Sequence
NO. for
Acid
Acid Corresponding To Amino Acid
SEQ ID SEQ ID
Amino Acid
Residues

(* Amino acid residues 117-438 for mutants 1-4 and resi
dues 117-441 for mutant 5.)

have enhanced catalytic activity. The method includes gener
20

a possible BChE mutant. A suf?ciently long time molecular
dynamics simulation is performed on the transition state

formulated in a pharmaceutical composition along with a
suitable pharmaceutical carrier known to one skilled in the
art.

structure in water to have a stable molecular dynamics traj ec
25

individual, an effective amount of one of the BChE variant

polypeptides, i.e., SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18,

variant is included with a suitable pharmaceutical carrier.
Treatment of a cocaine induced condition using one of the
aforementioned BChE variant polypeptides can be done in
accordance with Zhan et al., page 2463.
The preferred dose for administration of a butyrylcho
linesterase or peptide composition in accordance with the
present invention is that amount which will be effective in

lowering (—)-cocaine concentration in a patient’s blood
stream, and one would readily recognize that this amount will
vary greatly depending on the nature of cocaine consumed,
e.g., injected or inhaled, and the condition of a patient. An
“effective amount” of butyrylcholinesterase mutant or phar
maceutical agent to be used in accordance with the invention

tory. The molecular dynamics trajectory is analyzed and the
hydrogen binding energies are estimated between the car
boxyl oxygen of the (—)-cocaine benzoyl ester and the oxya
nion hole of the possible BChE mutant. If the overall hydro

The present BChE variant polypeptides can be used in
treating a cocaine-induced condition by administering to an

20, 22, 24, 26, 28, and 30, to lower blood cocaine concentra
tion. The BChE variant polypeptide may be administered in
the form of a pharmaceutical composition in which the BChE

ating an initial structure of the transition state structure for the

rate-determining step for the cocaine hydrolysis catalyzed by

The BChE variant polypeptide, e.g., SEQ ID NOS: 2, 4, 6,
8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30 can be

30

gen binding energy between the carboxyl oxygen of the (—)
cocaine benzoyl ester and the possible BChE mutant, in the
transition state, is stronger than the overall hydrogen binding
energy between the carboxyl oxygen of the (—)-cocaine ben

zoyl ester and the wild-type BChE, hybrid quantum mechani
cal/molecular mechanical (QM/MM) geometry optimization
35

40

is performed to re?ne the molecular dynamics-simulated
structure, the hydrogen binding energies are calculated and
the energy barrier is evaluated. The QM/MM calculations
make the computational predictions more reliable. Finally,
the BChE mutant is generated.
With regard to the molecular dynamics (MD) simulations
and quantum mechanical/molecular mechanical (QM/MM)
calculations, the ?rst chemical reaction step of (—)-cocaine

hydrolysis catalyzed by butyrylcholinesterase (BChE)
mutants and, when needed, other reaction steps are modeled
45

is intended to mean a nontoxic but suf?cient amount of the

and calculated using molecular dynamics simulations and
QM/MM calculations. Following this modeling, mutant

agent, such that the desired prophylactic or therapeutic effect

BChE’ s are created using site-directed mutagenesis followed

is produced. Thus, the exact amount of the enzyme or a

by protein expression. The afonnentioned ?ve mutants were

particular agent that is required will vary from subject to
subject, depending on the species, age, and general condition
of the subject, the severity of the condition being treated, the
particular carrier or adjuvant being used and its mode of

identi?ed by computational analysis and generated by site
50

administration, and the like. Similarly, the dosing regimen
should also be adjusted to suit the individual to whom the
composition is administered and will once again vary with

55

lead to a more stable transition state for the rate determining
60

the art using only routine experimentation.

if the predicted model indicates that the BChE variant should

step compared to the corresponding separated reagents, i.e.,
free cocaine and free possible mutant BChE, where the more

A unique method was used to determine potential BChE

mutants with projected increased catalytic activity for the
hydrolysis of cocaine. The method provides a unique
approach which ?rst models the potential BChE mutant inter
action with cocaine followed by generating the BChE mutant

of molecular modeling of a potential BChE mutant and MD
simulations and QM/MM calculations provide virtual screen

ing of possible BChE mutants which have predicted enhanced
catalytic activity for (—)-cocaine. For example, the MD simu
lations and QM/MM calculations predict which mutation will

age, weight, metabolism, etc. of the individual. Accordingly,
the “effective amount” of any particular butyrylcholinest
erase composition will vary based on the particular circum
stances, and an appropriate effective amount may be deter
mined in each case of application by one of ordinary skill in

directed mutagenesis which have signi?cantly enhanced (—)
cocaine hydrolysis catalytic ef?ciency compared with wild
type BChE.
In the present method computational analysis in the form

stable transition state leads to a lower energy barrier and

higher predicted catalytic ef?ciency. Only after the computa
tional analysis predicts enhanced catalytic ef?ciency, is site
65

directed mutagenesis conducted on wild-type BChE nucleic
acid sequence to generate a mutant nucleic acid sequence
which is then used to express a mutant BChE protein. The

US 8,835,150 B1
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mutant BChE protein is then used in catalytic assays to deter

art considered only one binding mode for each BChE-cocaine

mine the catalytic e?iciency against (—)-cocaine.

system, without modeling the possible cocaine rotation in the

The use of predictive, computational modeling of the
present method for identifying mutant BChE candidates and

BChE active site after the binding. The present method con
siders two different binding modes for each BChE-cocaine
system and the structural transformation between them: non

the resulting mutant BChE are novel and unexpected over

prior conventional methods which will now be readily appar

prereactive and prereactive BChE-cocaine complexes. The

ent to one of ordinary skill in the art.

present modeling provides more detailed information about
the BChE-cocaine binding and the subsequent structural

Using the present method, most discovered new mutants
include a speci?c mutation (Y332G) on residue #332. No
prior BChE mutant having the Y332G mutation had ever been
reported previously; only mutations Y332A and Y332M on
residue #332 had been tested previously by other researchers.

transformation.

The present method includes molecular dynamics simula
tions performed on the cocaine binding with both the wild
type BChE and the mutants whereas prior molecular dynam
ics simulations were only performed on the cocaine binding
with the wild-type BChE. As is shown below in the following

Prior to the present invention, there was no reason to expect

that a mutant includingY332G mutation should be better than
the corresponding mutant including Y332A mutation or
Y332M. Thus, the present mutants with a Y332G mutation

experiments, the computational prediction could be com

pletely wrong without directly modeling and simulating

which have enhanced cataltytic activity represent a surprising

cocaine binding with the proposed mutants.

and unexpected result over prior BChE mutants.
A Y332G mutant (single mutation) was ?rst tested and
found that the Y332G mutant had a slightly low (or approxi

the following non-limiting examples in the form of experi

The present invention will now be discussed with regard to

mately equal) catalytic ef?ciency than the wild-type. So, only

ments which are provided to enhance understanding of the
present invention but in no way limit its scope or applicability.

an appropriate combination of different mutations on differ
ent residues could make the enzyme more active. As seen

Experiment 1

20

below, the prior art did not reveal that any of the particular
combinations tested was expected to have an improved cata

25

lytic ef?ciency. The present method is based on the present

Computational Study of Cocaine Binding with
Wild-Type and Mutant BCHE’s for A328W/Y332G,
A328W/Y332A, and A328W/Y332A/Y419S

unique, extensive computational modeling and simulations of
the detailed catalytic mechanism for both the wild-type BChE

A detailed computational study of cocaine binding with

and the mutants.

The primary improvement of the present method over the

30

prior art is that high-performance computational modeling
and simulations of the detailed catalytic mechanism are per
formed, which includes modeling how cocaine binds with
BChE and the subsequent structural transformation and
chemical reaction process. The prior art only considered the
cocaine binding with the enzyme (BChE) and was unable to
examine the detailed catalytic reaction process after the
BChE-cocaine binding. When molecular modeling was lim
ited to studying the BChE-cocaine binding, one could only
design a mutation to improve the BChE-cocaine binding
without knowing whether the mutation will also speedup the

wild-type and mutant BChE’s starting from the available
X-ray crystal structure of wild-type BChE was performed.
The simulated mutants include A328W/Y332G, A328W/

Y332A, and A328W/Y332A/Y419S, as simple geometric
35

consideration of the binding site suggests that these mutations
could be important for changing the (—)-cocaine rotation from

the non-prereactive complex to the prereactive complex. Wet

40

experimental tests were conducted on the catalytic activity of
these mutants for (—)-cocaine in order to verify the computa
tional predictions. All of the obtained results clearly demon
strate that molecular modeling and MD simulations of
cocaine binding with BChE mutants provide a reliable com

subsequent chemical reaction process or not.

putational approach to the rational design of high-activity

To overcome the obstacles of prior challenges to using
computational techniques such as molecular docking and
molecular dynamics simulation previously used by others

mutants of BChE for the (—)-cocaine hydrolysis.
45

putational studies came from the X-ray crystal structure
deposited in the Protein Data Bank (pdb code: 1POP). The

which were based on an empirical force ?eld which cannot be

used to perform necessary reaction coordinate calculations
for the catalytic reaction process, a variety of state-of-the-art

computational techniques of homology modeling, molecular
docking, molecular dynamics, quantum mechanics (QM),

missing residues (D2, D3, E255, D378, D379, N455, L530,
E531, and M532) in the X-ray crystal structure were built
50

and hybrid quantum mechanics/molecular mechanics (QM/
MM) were used for the rational design of the BChE mutants.
The combined use of these computational techniques, includ

ing QM and QM/MM, led to the study of the detailed reaction
coordinate of the BChE-catalyzed hydrolysis of cocaine
which, for the ?rst time, provided the detailed structures of all

3D Model of BChE.
The initial coordinates of human BChE used in the com

55

using the automated homology modeling tool Modeler dis
closed by Sali,A.; Blundell, T. L. J. Mol. Biol. 1990, 212 403,
and Sali, A.; Blundell, T. L. J. Mol. Biol. 1993, 234, 779,

herein incorporated by reference, and lnsightll software (Ac
celrys, Inc.) with the default parameters.
Molecular Docking.
Molecular docking was performed for each non-prereac

transition states and intermediates existing in the reaction

tive protein-ligand binding complex. The binding site was

process and the corresponding energetics. These extensive
computational modeling and simulation studies provided for
the rational design of possible BChE mutants that not only
the subsequent chemical reaction process. As a result, one can

de?ned as a sphere with an approximately 15 A radius around
the active site residue S198. The amino acid residues included
in the binding site model are not contiguous in the protein.
Cocaine, considered as a ligand, was initially positioned at 17
A in front of S198 of the binding site. Each BChE-cocaine

now quickly discover the BChE mutants with the signi?

binding complex was energy-minimized by using the steepest

60

can improve the BChE-cocaine binding, but also can speedup

cantly improved catalytic ef?ciency.
In addition, to the differences mentioned above, the present
molecular modeling of the BChE-cocaine binding also differs

from the prior modeling. The molecular modeling in the prior

65

descent algorithm ?rst until the maximum energy derivative
is smaller than 4 kcal/mol/A and then the conjugated gradient
algorithm until the maximum energy derivative is smaller
than 0.001 kcal/mol/A. The energy minimization was fol
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lowed by a 300 ps molecular dynamics (MD) simulation at
T:298 K with a time step of 1 fs. During the energy minimi
zation and MD simulation, only cocaine and the residues of

interactions.A residue-based cutoff of 10 Awas applied to the
noncovalent interactions. During the 500 ps production MD
simulation, the coordinates of the simulated complex were

BChE included in the binding site were allowed to move,

saved every 1 ps.

while the remaining part of the protein was ?xed. The energy

Molecular docking and MD simulation procedures
described above were performed to study cocaine binding
with wild-type BChE and three mutants, i.e., A328W/
Y332A, A328W/Y332A/Y419S, and A328W/Y332G. For
each protein system (wild-type or mutant BChE), the protein

minimization and MD simulation for these processes were

performed by using the Amber force ?eld implemented in the
Discoveri3/InsightII calculation engine, disclosed by Cor
nell, W. D.; Cieplak, P.; Bayl), C. I.; Gould, I. R.; Merz, Jr., K.
M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J.

binding with cocaine was considered in both the non-prere

active and prereactive enzyme-substrate complexes.

W.; Kollman, P. A. J. Am. Chem. Soc. 1995, 117, 5179. The

Most of the MD simulations in water were performed on a

non-bonded cut-off method and the dielectric constant were

supercomputer, Superdome (shared-memory, with 4 nodes

set up to group based (12 A cut-off distance) and distance

and 256 processors), at the Center for Computational Sci
ences, University of Kentucky. The other computations were

dependent, respectively (6:4r) in accordance with Harvey, S.
C. Proteins 1989, 5, 78-92, herein incorporated by reference.

carried out on SGI Fuel workstations and a 34-processors

Molecular Dynamic Simulation in Water.

IBM x335 Linux cluster.

The initial coordinates used in the MD simulation of the

Experimental Procedure.

non-prereactive complexes were determined by using the
molecular docking procedure described above, whereas the

Site-directed mutagenesis of human BChE cDNA was per

initial coordinates used in the MD simulation of the prereac
tive complexes were obtained from superimposing backbone
of the X-ray crystal structure to that of the previously dis
closed simulated prereactive complex of Zhan et al between
cocaine and a homology model of wild-type BChE. Each

BChE-cocaine binding complex was neutralized by adding

25

1999, 55, 83, all herein incorporated by reference, kindly

two chloride counterions and was solvated in a rectangular
box of TIP3P water molecules with a minimum solute-wall

provided by Dr. Lockridge at University of Nebraska Medical
Center. Using plasmid DNA as template and primers with
speci?c base-pair alterations, mutations were made by poly

distance of 10 A. The general procedure for carrying out the
MD simulations in water is similar to that used in our previ

ously reported other computational studies such as those in
Zhan et al and (a) Zhan, C.-G.; Norberto de Souza, O.; Rit
tenhouse, R.; Omstein, R. L. J. Am. Chem. Soc. 1999, 121,

7279, (b) Koca, J .; Zhan, C.-G.; Rittenhouse, R.; Omstein, R.
L. J Am. Chem. Soc. 2001, 123, 817, (c) Koca, J.; Zhan,
C.-G.; Rittenhouse, R. C.; Omstein, R. L. J. Compul. Chem.
2003, 24, 368, herein all incorporated by reference. These
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Cheng,A. L.; Vincent, J. J.; Crowley, M.; Tsui, V.; Gohlke, H.;
Radmer, R. J.; Duan,Y.; Pitera, J.; Massova, I.; Seibel, G. L.;

endonuclease to digest the parental DNA template. Modi?ed

35

?ed, and puri?ed. The DNA sequences of the mutants were
con?rmed by DNA sequencing. BChE mutants were

expressed in human embryonic kidney cell line 293T/ 17.
Cells were grown to 80-90% con?uence in 6-well dishes and

then transfected by Lipofectamine 2000 complexes of 4 pg
40

Singh, U. C.; Weiner, P. K.; Kollman, P. A. (2002),AMBER 7,
University of California, San Francisco, herein incorporated
by reference. The solvated system was optimized prior to the
MD simulation. First, the protein-ligand was frozen and the

merase chain reaction with Pfu DNA polymerase, for repli
cation ?delity. The PCR product was treated with Dpn I

plasmid DNA was transformed into Escherichia coli, ampli

simulations were performed by using the Sander module of
Amber7 program as taught by Case, D. A.; Pearlman, D. A.;

Caldwell, J. W.; Cheatham III, T. E.; Wang, J.; Ross, W. S.;
Simmerling, C. L.; Darden, T.A.; Merz, K. M.; Stanton, R.V.;

formed by the QuikChange method of Braman, J .; Papworth,
C.; Greener, A. Methods Mol. Biol. 1996, 57, 5731, herein
incorporated by reference. Mutations were generated from
wild-type human BChE in a pRc/CMV expression plasmid in
accordance with Xie, W.; Altamirano, C. V.; Bartels, C. F.;
Speirs, R. J.; Cashman, J. R.; Lockridge, 0. Mol. Pharmacol.

plasmid DNA per each well. Cells were incubated at 37° C. in
a C02 incubator for 24 hours and cells were moved to 60-mm
culture vessel and cultured for four more days. The culture
medium [10% fetal bovine serum in Dulbecco’s modi?ed
Eagle’ s medium (DMEM)] was harvested for a BChE activity
assay. To measure cocaine and benzoic acid, the product of

cocaine hydrolysis by BChE, we used sensitive radiometric
45

assays based on toluene extraction of [3H] cocaine labeled on

solvent molecules with counterions were allowed to move

its benzene ring were used in accordance with Masson, P.;

during a 5000-step minimization with the conjugate gradient

Xie, W., Froment, M-T.; Levitsky, V.; Fortier, P.-L.; Albaret,

algorithm and a 5 ps MD run at T:300 K. After full relaxation

C.; Lockridge, O. Biochim. Biophys. Acta 1999, 1433, 281,

and the entire solvated system was energy-minimized, the
system was slowly heated from T:10 K to T:300 K in 30 ps
before the production MD simulation for 500 ps. The full

herein incorporated by reference. In brief, to initiate reac
tions, 100 nCi of [3H]cocaine was mixed with 100 pl of
culture medium. Reactions proceeded at 370 C. for varying
times. Reactions were stopped by adding 300 pl of 0.02 M
HCl, which neutralized the liberated benzoic acid while
ensuring a positive charge on the residual cocaine. [3H]ben
zoic acid was extracted by 1 ml of toluene and measured by

50

minimization and equilibration procedure was repeated for
each mutant. The MD simulations were performed with a

periodic boundary condition in the NPT ensemble at T:300 K
with Berendsen temperature coupling and constant pressure

(P:1 atm) with isotropic molecule-based scaling disclosed in

55

scintillation counting. Finally, the measured time-dependent

Berendsen, H. C.; Postma, J. P. M.; van Gunsteren, W. F.;

radiometric data were ?tted to the kinetic equation so that the

DiNola, A.; Haak, J. R. J. Comp. Phys. 1984, 81, 3684, herein
incorporated by reference. The SHAKE algorithm of Ryck
aert, J. P.; Ciccotti, G.; Berendsen, H. C.J. Comp. Phys. 1977,
23, 327 (herein incorporated by reference) was applied to ?x

catalytic ef?ciency (km/KM) was determined.
Depicted in FIG. 1 are plots of some important distances in

the MD-simulated (—)-cocaine binding with A328W/Y332G
BChE versus the simulation time, along with root-mean
square deviation (RMSD) of the coordinates of backbone
atoms in the simulated structure from those in the X-ray
crystal structure. MD trajectories for other complexes were
similar to these two in FIG. 1, although the simulated average

all covalent bonds containing a hydrogen atom, a time step of
2 fs was used, and the non-bond pair list was updated every 10

steps. The pressure was adjusted by isotropic position scaling.
The particle mesh Ewald (PME) method of Essmann, U.;
Perera, L.; Berkowitz, M. L.; Darden, T. A.; Lee, H., Peder
sen; L. G. J. Chem. Phys. 1995, 98, 10089, herein incorpo
rated by reference, was used to treat long-range electrostatic
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distances are different. Summarized in Table 2 are the average

values of some important geometric parameters in the simu

lated complexes.
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TABLE 2
Average values of the geometric parameters
BChE—cocaine binding“

<D1>,mn <D1> <D2> <D3> <D4> <®>

wild-type

5.77

2.71

3.37

RMSDd

0

5.60

3.27

67

wild—type with (+)—cocainel7

7.64

3.69

2.88

3.30

2.83

61

A328W/Y332A
A328W/Y332G
A328W/Y332A/Y419S

7.11
7.06
5.18

3.87
3.96
5.84

3.30
2.28
5.64

2.14
2.52
4.56

3.01
2.42
6.97

51
60
164

nonpre

pre

1.14
1.15
1.58
1.20
2.66

1.27
1.13
1.65
1.35
2.62

The simulated internuclear distances between the carbonyl
oxygen of cocaine benzoyl ester group and the NH hydrogen

“Refers to (—)-cocaine binding with wild-type human
BChE or (—)-cocaine binding with a mutant BChE, unless
indicated otherwise.

of G1 16, G117, and A199 are comparable for the two enan
tiomers. The simulated average distances between the carbo
nyl carbon of the benzoyl ester and S198 OY are 5.60 A and

[Refers to (+)-cocaine binding with wild-type human
BChE.

C<D1>n0n and <D1> represent the average distances
between the S198 OY atom and the carbonyl carbon of the
cocaine benzoyl ester in the simulated non-prereactive and

5.18 A for (—)- and (+)-cocaine, respectively. Comparing the
simulated protein backbone structures to the X-ray crystal
20

structure of Nicolet et a1, one can see from FIG. 1 that the

prereactive BChE-cocaine complexes, respectively. <D2>,

RMSD values are all smaller than 1.3 A for the whole protein

<D3>, <D4> refer to the average values of the simulated

structures.

distances from the carbonyl oxygen of the cocaine benzoyl
ester to the NH hydrogen atoms of G116, G117, and A199
residues, respectively. <®> is the average value of the dihe
dral angle formed by the S198 OY atom and the plane of the
carboxylate group of the cocaine benzoyl ester. See Scheme

The MD simulations of the prereactive complexes reveal

that wild-type BChE binding with (—)-cocaine is essentially
25

the same as the binding with (+)-cocaine in the binding site,
except for the different positions of methyl ester group of the
substrates. The simulated average distances between the car

2.

bonyl carbon of the benzoyl ester and S198 OY are 3.27 and

“The root-mean-square deviation (RMSD) of the coordi
nates of backbone atoms in the simulated structure from those

3.69 A for (—)-cocaine and (+)-cocaine, respectively. More
30

in the X-ray crystal structure of BChE. “nonpre” and “pre”
refer to the non-prereactive and prereactive BChE-cocaine

complexes, respectively.

Table 2. The cocaine benzoyl ester moiety is positioned quasi

(—)- and (+)-Cocaine Binding with Wild-Type BChE.
FIG. 2 shows the binding structures of the simulated non

perpendicular to S198 C40Y with a dihedral angle 6 of ~670
35

prereactive and prereactive complexes of wild-type BChE

and ~61o for (—)- and (+)-cocaine, respectively.
A comparison was made between the currently simulated
structures of the BChE-cocaine binding with those simulated
previously by using a homology model of BChE and it was
noted that two major differences between the two sets of

binding with the two enantiomers of cocaine. In the non

prereactive complexes with (—)- and (+)-cocaine, the methyl
ester group of cocaine is positioned at the top of the H438

backbone, while the cocaine benzoyl ester moiety is quasi

over, the (+)-cocaine is stabilized more effectively by the
formation of strong hydrogen bonds with the backbone NH of
residues G116, G117, and A199 as summarized above in

40

parallel to the CiOY side chain of S 1 98 with a dihedral angle

6) of —80 and 140°, respectively.

45

structures. By using the X-ray crystal structure in accordance
with Nicolet et al, the acyl loop is positioned on the top of the
cocaine benzoyl ester moiety of the cocaine, whereas the acyl
loop is far from the cocaine benzoyl ester moiety in the
structure simulated starting from the homology model of
Zhan et al. The RMSD of the coordinates of backbone atoms

in the previously simulated prereactive BChE-(—)-cocaine

50

complex from those in the X-ray crystal structure of BChE is
~2.0 A for the entire protein and ~3 .0 A for the acyl loop. The
RMSD value became ~2.4 A for the entire protein and ~3.3 A
for the acyl loop, when the X-ray crystal structure was

replaced by the MD-simulated prereactive BChE-(—)-cocaine
complex starting from the X-ray crystal structure. Despite
55

these structural differences, the benzoyl ester group of the
ligand is still close to the key residues (S197, G116, and
G1 17) in the BChE binding site. Some signi?cant differences
are associated with the distances between the S198 OY atom

and the carbonyl carbon of the cocaine benzoyl ester in non

60

prereactive complexes. The average values of this distance in
the non-prereactive complexes were ~9.5 and ~8.5 A for (—)
and (+)-cocaine, respectively, when a homology model was
used. Using the X-ray crystal structure to conduct the analy
sis, corresponding average values became ~5.6 and ~5.2 A,

respectively. Therefore, both (—)- and (+)-cocaine became
closer to the binding site when the homology model was

Scheme 2. Hydrolysis of (—)-cocaine and (+)-cocaine.
Here, 6) refers to the dihedral angle formed by S198 0V and
the plane of carboxylate group of the cocaine benzoyl ester as
shown in the structure diagram below.
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replaced by the X-ray crystal structure. However, no signi?
cant changes of the binding in the prereactive complexes were
observed when the used homology model was replaced by the

US 8,835,150 B1
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X-ray crystal structure. The average values of the simulated
distance between the S198 OY atom and the carbonyl carbon
of the cocaine benzoyl ester in the prereactive complexes are
always close to ~3 .5 A for both (—)- and (+)-cocaine no matter
whether the X-ray crystal structure or homology model of

suggesting that the energy barrier for the (—)-cocaine rotation
in A328W/Y332G BChE should be slightly lower than that in
A328W/Y332A BChE.

Concerning (—)-cocaine binding with A328W/Y332A/
Y419S BChE,Y419 stays deep inside the protein and does not
directly contact with the cocaine molecule. The Y4 1 9S muta
tion was tested because it was initially expected that this
mutation would further increase the free space of the active
site pocket so that the (—)-cocaine rotation could be easier.
However, as seen in Table 2 above, the average distance

BChE was used as the starting structure. The similar compu

tational results obtained from the use of the X-ray crystal
structure and homology model of BChE provides evidence
that the fundamental structural and mechanistic insights
obtained from the previous computational studies of Zhan et
al are reliable, despites the previous simulations were per

between the carbonyl carbon of cocaine benzoyl ester and

formed by using the homology model when the X-ray crystal

S198 OY atom in the simulated prereactive complex was as

structure was not available.

long as 5.84 A. The average distances between the carbonyl
oxygen of the cocaine benzoyl ester and the NH hydrolysis

Further, the simulated structures of the non-prereactive
BChE-cocaine complexes were superimposed with the cor

atoms of G116, G117, and A199 residues are between 4.56
and 6.97 A; no any hydrogen bond between them. In addition

responding prereactive complexes. As shown in FIG. 3, the

to the internuclear distances, another interesting geometric
parameter is the dihedral angle, 6), formed by S198 0V and the
plane of the carboxylate group of the cocaine benzoyl ester.

(—)-cocaine rotation in the BChE active site from the non

prereactive complex to the prereactive complex is hindered
by some residues as the positions on332, A328, and F329
residues in the non-prereactive complex are signi?cantly dif
ferent from the corresponding positions in the prereactive
complex, whereas none of these residues hinders the (+)

20

cocaine rotation in the BChE active site from the non-prere

active complex to the prereactive complex because these resi
dues stay in nearly the same positions in the two BChE-(+)

25

cocaine complexes.
(—)-Cocaine Binding with BChE Mutants.

prereactive complex of (—)-cocaine with A328W/Y332A/
Y419S BChE is 164°, which is considerably different from
the ideal value of 90°.

Catalytic Activity.

Now that the (—) -cocaine rotation from the non-prereactive
complex to the prereactive complex has been known to be the

rate-determining step of the BChE-catalyzed hydrolysis of

As seen in Table 2, the 6) values in the prereactive complexes
of cocaine with wild-type BChE and all of the BChE mutants
other than A328W/Y332A/Y419S BChE all slightly deviate
from the ideal value of 90° for the nucleophilic attack of S 1 98
0V at the carbonyl carbon of cocaine. The 6) value in the

30

The aforementioned discussion provides evidence that the
energy barriers for the (—)-cocaine rotation in A328W/

(—)-cocaine as shown by Zhan et al, useful BChE mutants

Y332A and A328W/Y332G BChE’s from the non-prereac

should be designed to speci?cally accelerate the change from
the non-prereactive BChE-(—)-cocaine complex to the prere

tive complex to the prereactive complex, the rate-determining
step for the BChE-catalyzed hydrolysis of (—)-cocaine,

active complex. The question is whether MD simulation can

be performed to help design BChE mutants that have higher

35

catalytic activity for (—)-cocaine hydrolysis.

ity than the wild-type BChE for (—)-cocaine hydrolysis. Fur

In the simulated non-prereactive complex, the average dis
tance between the carbonyl carbon of cocaine benzoyl ester
and S198 0V is 7.6 A forA328W/Y332A BChE and 7.1 A for
A328W/Y332G BChE, as seen in Table 2 above. In the simu

40

lated prereactive complex, the average values of this impor

ther, the MD simulations also suggest that the energy barrier
for the (—)-cocaine rotation in A328W/Y332G BChE should
be slightly lower than that in A328W/Y332A BChE and,

therefore, the catalytic activity of A328W/Y332G BChE for
the (—)-cocaine hydrolysis should be slightly higher than the

tant internuclear distance become 3.87 and 3.96 A for

A328W/Y332A and A328W/Y332G BChE’s, respectively.
Compared to the simulated wild-type BChE-(—)-cocaine pre
reactive complex, the average distances between the carbonyl

should be lower than that in the wild-type BChE. Thus, the
MD simulations predict that both A328W/Y332A and
A328W/Y332G BChE’ s should have a higher catalytic activ

activity of A328W/Y332A BChE. In addition, the MD simu
lations predict that A328W/Y332A/Y419S BChE should
45

have no catalytic activity, or have a considerably lower cata

carbon of the cocaine benzoyl ester and S198 0V in the pre

lytic activity than the wild-type, for (—)-cocaine hydrolysis

reactive complex of (—)-cocaine with A328W/Y332A and

because (—)-cocaine binds with the mutant BChE in a way
that is not suitable for the catalysis.

A328W/Y332G BChE’s are all slightly longer, whereas the
average distances between the carbonyl oxygen of the
cocaine benzoyl ester and the NH of G1 16, G117, and A199
residues are all shorter. This provides evidence that (—)-co
caine more strongly bind with A328W/Y332A and A328W/

The catalytic ef?ciency (km/KM) of A328W/Y332A
50

M min—l, which is 9.39 times ofthe kcat/KMvalue (9.11><105

Y332G BChE’s in the prereactive complexes. More impor
tantly, the (—)-cocaine rotation in the active site of A328W/
Y332A and A328W/Y332G BChE’s from the non

BChE for (—)-cocaine hydrolysis was reported to be 8.56><106

55

M min—l) of the wild-type BChE. To examine these theoreti
cal predictions of the relative activity forA328W/Y332G and
A328W/Y332A/Y419S BChE’s, aA328W/Y332A, A328W/
Y332G, and A328W/Y332A/Y419S BChE was produced

through site-directed mutagenesis. To minimize the possible

prereactive complex to the prereactive complex did not cause

considerable changes of the positions of A332 (or G332),

systematic experimental errors of the kinetic data, kinetic

W328, and F329 residues as seen in FIG. 4, compared to the

studies were performed with all of three mutants under the

(—)-cocaine rotation in the active site of wild-type BChE.
These results provide evidence that A328W/Y332A and
A328W/Y332G BChE’s should be associated with lower
energy barriers than the wild-type for the (—) -cocaine rotation

same condition and compared the catalytic ef?ciency of the
60

A328W/Y332A for (—)-cocaine hydrolysis at benzoyl ester
group. Based on the kinetic analysis of the measured time

from the non-prereactive complex to the prereactive complex.
Further, (—)-cocaine binding with A328W/Y332G BChE is
very similar to the binding with A328W/Y332A BChE, but

the position change of F329 residue caused by the (—)-cocaine
rotation was signi?cant only in A328W/Y332A BChE, thus

A328W/Y332G and A328W/Y332A/Y419S to that of the

dependent radiometric data, the ratio of the kcat/KM value of
65

A328W/Y332G BChE to the kcat/KM value of A328W/
Y332A BChE for the (—)-cocaine hydrolysis was determined
to be ~2.08, or A328W/Y332G BChE has a kcat/KM value of
~1.78><107 M min“ 1 for the (—) -cocaine hydrolysis. The radio

US 8,835,150 B1
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metric data show no signi?cant catalytic activity forA328W/

A328W/Y332A BChE, but the position change of F329 resi
due caused by the (—)-cocaine rotation was signi?cant only in
A328W/Y332A BChE, thus suggesting that the energy bar
rier for (—)-cocaine rotation in A328W/Y332G BChE should

Y332A/Y419S BChE. These experimental data are consis
tent with the theoretical predictions based on the MD
simulations.
Conclusion.

be slightly lower than that in A328W/Y332A BChE. It has
also been demonstrated that (—)-cocaine binds with A328W/

Molecular modeling, molecular docking, and molecular
dynamics (MD) simulations were performed to study cocaine
binding with human butyrylcholinesterase (BChE) and its

Y332A/Y419S BChE in a way that is not suitable for the

catalysis.
Based on the computational results, both A328W/Y332A

mutants, based on a recently reported X-ray crystal structure
of human BChE. The MD simulations of cocaine binding
with wild-type BChE led to average BChE-cocaine binding
structures similar to those obtained recently from the MD
simulations based on a homology model of BChE, despite the

and A328W/Y332G BChE’s have catalytic activity for (—)
cocaine hydrolysis higher than that of wild-type BChE and
the activity of A328W/Y332G BChE should be slightly
higher than that of A328W/Y332A BChE, whereas A328W/
Y332A/Y419S BChE is expected to lose the catalytic activ
ity. The computational predictions are completely consistent
with the experimental kinetic data, providing evidence that
the used computational protocol, including molecular mod
eling, molecular docking, and MD simulations, is reliable in
prediction of the catalytic activity of BChE mutants for (—)

signi?cant difference found at the acyl binding pocket. This
con?rms the fundamental structural and mechanistic insights
obtained from the prior computational studies of Zhan et al
based on a homology model of BChE, e.g., the rate-determin

ing step for BChE-catalyzed hydrolysis of biologically active
(—)-cocaine is the (—)-cocaine rotation in the BChE active site
from the non-prereactive BChE-(—)-cocaine complex to the

cocaine hydrolysis.
20

Experiment 2

prereactive complex.
The MD simulations further reveal that the (—)-cocaine
rotation in the active site of wild-type BChE from the non

MD Simulations and Quantum
Mechanical/Molecular Mechanical (QM/MM)

prereactive complex to the prereactive complex is hindered

Calculations Relating to Al 995/A328W/Y332G

by some residues such that the positions ofY332, A328, and
F329 residues in the non-prereactive complex are signi?
cantly different from those in the prereactive complex. Com

Mutant (Mutant l) (SEQ ID NO: 1)
Generally speaking, for rational design of a mutant enzyme
with a higher catalytic activity for a given substrate, one needs

pared to (—)-cocaine binding with wild-type BChE, (—)-co

to design a mutation that can accelerate the rate-determining

caine more strongly bind with A328W/Y332A and A328W/

Y332G BChE’s in the prereactive complexes. More
importantly, the (—)-cocaine rotation in the active site of
A328W/Y332A and A328W/Y332G BChE’s from the non

prereactive complex to the prereactive complex did not cause
considerable changes of the positions of A332 or G332,
W328, and F329 residues. These results provide evidence that
A328W/Y332A and A328W/Y332G BChE’s are associated

with lower energy barriers than wild-type BChE for the (—)
cocaine rotation from the non-prereactive complex to the

prereactive complex. Further, (—)-cocaine binding with
A328W/Y332G BChE is very similar to the binding with

30

step of the entire catalytic reaction process while the other
steps are not slowed down by the mutation. Reported com

putational modeling and experimental data indicated that the
formation of the prereactive BChE-(—) -cocaine complex (ES)
is the rate-determining step of (—)-cocaine hydrolysis cata
lyzed by wild-type BChE as disclosed by Sun et al, Zhan et al

and Hamza, A.; Cho, H.; Tai, H.-H.; Zhan, C.-G. J. Phys.
Chem. B 2005, 109, 4776, herein incorporated by reference,
whereas the rate-determining step of the corresponding (+)
cocaine hydrolysis is the chemical reaction process consist
ing of four individual reaction steps disclosed by Zhan et al
and shown in Scheme 3 and Scheme 4 below.

